Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Rauchmann

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Neurology|March 25, 2025
Vestibular dysfunction: a hidden risk factor for Alzheimer's diseaseCarolin Anna Maria Koriath, Boris Rauchmann, Florian Schoeberl, et al.
European Archives of Psychiatry and Clinical Neuroscience|May 23, 2019
Neurobiological effects of aerobic exercise, with a focus on patients with schizophreniaIsabel Maurus, Alkomiet Hasan, Astrid Röh, et al.
Frontiers in Psychiatry|January 10, 2019
Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased MortalityAndrea Schmitt, Isabel Maurus, Moritz J Rossner, et al.
Plos One|May 2, 2024
Short communication: Lifetime musical activity and resting-state functional connectivity in cognitive networksMaxie Liebscher, Andrea Dell'Orco, Johanna Doll-Lee, et al.
Alzheimer'S Research & Therapy|October 17, 2020
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers-results from the DELCODE studyLena Sannemann, Ann-Katrin Schild, Slawek Altenstein, et al.
Alzheimer'S Research & Therapy|November 24, 2021
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's diseaseMartin Dyrba, Moritz Hanzig, Slawek Altenstein, et al.
Molecular Psychiatry|April 17, 2025
Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s diseaseDavid Mengel, Ester Soter, Julia Maren Ott, et al.
Neurology|May 6, 2021
Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old AgeTommaso Ballarini, Debora Melo van Lent, Julia Brunner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 22, 2022
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centersFrank Jessen, Steffen Wolfsgruber, Luca Kleineindam, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 28, 2024
Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's diseaseJonathan Vogelgsang, Niels Hansen, Melina Stark, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Neurology|March 25, 2025
Vestibular dysfunction: a hidden risk factor for Alzheimer's diseaseCarolin Anna Maria Koriath, Boris Rauchmann, Florian Schoeberl, et al.
European Archives of Psychiatry and Clinical Neuroscience|May 23, 2019
Neurobiological effects of aerobic exercise, with a focus on patients with schizophreniaIsabel Maurus, Alkomiet Hasan, Astrid Röh, et al.
Frontiers in Psychiatry|January 10, 2019
Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased MortalityAndrea Schmitt, Isabel Maurus, Moritz J Rossner, et al.
Plos One|May 2, 2024
Short communication: Lifetime musical activity and resting-state functional connectivity in cognitive networksMaxie Liebscher, Andrea Dell'Orco, Johanna Doll-Lee, et al.
Alzheimer'S Research & Therapy|October 17, 2020
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers-results from the DELCODE studyLena Sannemann, Ann-Katrin Schild, Slawek Altenstein, et al.
Alzheimer'S Research & Therapy|November 24, 2021
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's diseaseMartin Dyrba, Moritz Hanzig, Slawek Altenstein, et al.
Molecular Psychiatry|April 17, 2025
Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s diseaseDavid Mengel, Ester Soter, Julia Maren Ott, et al.
Neurology|May 6, 2021
Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old AgeTommaso Ballarini, Debora Melo van Lent, Julia Brunner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 22, 2022
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centersFrank Jessen, Steffen Wolfsgruber, Luca Kleineindam, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 28, 2024
Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's diseaseJonathan Vogelgsang, Niels Hansen, Melina Stark, et al.
Pageof 1